Lemonex
LemonexBio is a global biotherapeutics biotechnology company specializing in innovative next-generation drug delivery technology, DegradaBALL®. They are developing and commercializing immuno-oncology drugs, antibody medicines, gene therapies, and mRNA based on their proprietary platform.
Industries
Nr. of Employees
small (1-50)
Lemonex
Products
siRNA therapeutic candidate for hypertrophic/keloid scarring (pipeline)
siRNA-based therapeutic candidate formulated to protect siRNA from degradation and enable targeted delivery for treatment of hypertrophic scars and keloids.
mRNA COVID-19 vaccine candidate (pipeline)
mRNA vaccine candidate developed to improve safety, immune durability, and thermal stability compared with prior mRNA vaccine formulations.
Dual-RNA immuno-oncology candidate (pipeline)
RNA-based oncology candidate combining two RNA modalities to activate anti-tumor immunity and overcome immune suppression, intended to enhance systemic and abscopal anti-tumor effects.
Cytokine (IL-2) controlled-release immuno-oncology candidate (pipeline)
Cytokine-based immuno-oncology candidate formulated for controlled release to limit systemic exposure and improve therapeutic window of cytokine therapies.
GMP-certified sterile vial production infrastructure
On-site GMP-certified manufacturing infrastructure capable of producing sterile vials with stated annual capacity of approximately 450,000 vials to support clinical and commercial supply.
siRNA therapeutic candidate for hypertrophic/keloid scarring (pipeline)
siRNA-based therapeutic candidate formulated to protect siRNA from degradation and enable targeted delivery for treatment of hypertrophic scars and keloids.
mRNA COVID-19 vaccine candidate (pipeline)
mRNA vaccine candidate developed to improve safety, immune durability, and thermal stability compared with prior mRNA vaccine formulations.
Dual-RNA immuno-oncology candidate (pipeline)
RNA-based oncology candidate combining two RNA modalities to activate anti-tumor immunity and overcome immune suppression, intended to enhance systemic and abscopal anti-tumor effects.
Cytokine (IL-2) controlled-release immuno-oncology candidate (pipeline)
Cytokine-based immuno-oncology candidate formulated for controlled release to limit systemic exposure and improve therapeutic window of cytokine therapies.
GMP-certified sterile vial production infrastructure
On-site GMP-certified manufacturing infrastructure capable of producing sterile vials with stated annual capacity of approximately 450,000 vials to support clinical and commercial supply.
Services
Strategic development collaborations for vaccine delivery
Collaborative development partnerships aimed at advancing mRNA vaccine delivery and pandemic preparedness using the company's delivery platform.
Strategic development collaborations for vaccine delivery
Collaborative development partnerships aimed at advancing mRNA vaccine delivery and pandemic preparedness using the company's delivery platform.
Expertise Areas
- Drug delivery systems
- Nucleic acid therapeutics development
- mRNA vaccine development
- Immuno-oncology therapeutic development
Key Technologies
- Degradable nanoparticle-based drug delivery
- siRNA delivery formulations
- mRNA vaccine platforms
- Dual-RNA therapeutic constructs